The programmed cell death protein 1 (PD‐1) inhibitor, as an immune checkpoint inhibitors (ICIs), has become the first‐line therapy in advanced stages of different tumor types1, 2 and is increasingly used in early‐stage disease settings, including advanced lung cancer.3 Here, PDCD1 is linked to lung cancer.